Saturday 17 October 2026 Export IMNN’s income statement to Excel — free account

Imunon, Inc.

Imunon, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $500,000.00. In the quarter to June 2026, EPS grew 71.1% and free cash flow fell 4.24%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.02 0.04 −3.77%

Follow IMNN

Alert me

Market cap: $6.0M
P/E: 0.0×
Fwd P/E: −0.5×
Dividend yield: —
F-score: 2/9
Altman Z: −12.47
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.04

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	1	2	3	—	—

Insider Ownership 7.50%

Capital & Financial Ratios $m

Market Cap 5.95

Revenue 0.50

Net Income (14.71)

Free Cash Flow (15.20)

Net Debt (1.33)

Current Ratio 1.82

Debt/Equity 1.32

P/E ratio 0.00

Fwd P/E (0.51)

P/S ratio 10.67

P/B ratio 2.76

Past 5Y EPS Growth —

This Y EPS Growth 65.42%

Next Y EPS Growth 22.95%

Next Y revenue growth (66.00%)

Next 5Y EPS Growth 41.53%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.70%

10-year low 10-year high

P/B against its own 10 years 78.84%

10-year low 10-year high

EV/Sales against its own 10 years 9.48%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	16	6	9	7
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	3	2	2	2
	18	8	11	9

	2023	2024	2025	Q'26
Payables	4	1	1	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	7	5	5	5

Compound Annual Growth %

	10y	5y	3y
Sales	(12.94%)	0.00%	0.00%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(10.06%)	(17.62%)	(37.79%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	0	0	0	0	1
’21	0	0	0	0	1
’20	0	0	0	0	1
’19	0	0	0	0	1
’18	0	0	0	0	1
’17	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(3)	—	—	—
’25	(3)	(3)	(4)	(4)	(14)
’24	(6)	(5)	(4)	(4)	(19)
’23	(4)	(7)	(4)	(4)	(19)
’22	(8)	(5)	(5)	(5)	(23)
’21	(5)	(3)	(4)	(5)	(16)
’20	(5)	(3)	(4)	(4)	(16)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(3)	—	—	—
’25	(3)	(3)	(4)	(4)	(14)
’24	(6)	(5)	(4)	(4)	(19)
’23	(4)	(7)	(5)	(4)	(19)
’22	(8)	(6)	(5)	(5)	(23)
’21	(5)	(3)	(4)	(5)	(17)
’20	(5)	(3)	(4)	(4)	(16)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.84)	(0.54)	—	—	—
’25	(3.65)	(1.87)	(1.16)	(1.29)	(6.83)
’24	(6.78)	(6.65)	(4.43)	(3.00)	(21.12)
’23	(8.87)	(7.95)	(4.82)	(6.78)	(28.16)
’22	(23.73)	(11.34)	(11.34)	(20.99)	(65.58)
’21	(43.11)	(11.73)	(11.73)	17.84	(49.93)
’20	(39.09)	(35.18)	(46.91)	(9.77)	(130.96)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	794.35	242.61	264.13	205.43	84.13	105.65	16.43	8.22	6.26	2.99	Analyst estimates 2026–2028 Powerpack
	High	5,450.87	1,725.65	680.87	514.57	1,271.74	680.87	121.30	22.43	47.61	41.22
People
People	Employees	19	21	29	29	27	29	31	33	25	20
	Revenue/emp, $m	0.03	0.02	0.02	0.02	0.02	0.02	0.02	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	1	1	1	1	1	1	1	—	—	—
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	—	—	—
	EBT	(22)	(20)	(22)	(19)	(23)	(22)	(37)	(21)	(19)	(14)
	EBT margin, %	(4,410.74)	(4,080.44)	(4,460.50)	(3,733.60)	(4,665.88)	(4,430.54)	(7,493.06)	0.00	0.00	0.00
	Net income	(22)	(20)	(12)	(17)	(21)	(21)	(36)	(20)	(19)	(14)
	Depreciation	1	1	1	1	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	52.63	12.82	5.56	4.48	3.06	1.20	0.91	0.00	0.00	0.00
	Earnings	(2,326.86)	(531.64)	(132.91)	(150.50)	(130.96)	(49.93)	(65.58)	(28.16)	(21.12)	(6.83)
	Cash flow	(1,934.67)	(426.72)	(78.24)	(181.37)	(95.59)	(38.97)	(42.16)	(27.42)	(17.16)	(6.54)
	Capex	(6.58)	(0.99)	(1.54)	(3.13)	(0.12)	(0.75)	(0.49)	(0.65)	(0.03)	(0.13)
	Free cash flow	(1,941.25)	(427.71)	(79.78)	(184.50)	(95.70)	(39.72)	(42.64)	(28.07)	(17.18)	(6.68)
	Book value	707.98	684.73	231.79	130.34	113.90	134.03	53.53	19.30	3.86	3.33
	Shares, m	0	0	0	0	0	0	1	1	1	2
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	P/S	16.65	43.04	49.66	74.74	45.40	87.96	21.44	—	—	—
	P/B	1.24	0.81	1.19	2.57	1.22	0.79	0.37	—	—	—
	EV/Sales	10.68	(2.66)	13.27	60.95	18.94	0.89	(37.83)	—	—	—
	EV/FCF	(0.29)	0.08	(0.92)	(1.48)	(0.61)	(0.03)	0.81	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(18)	(17)	(7)	(20)	(16)	(16)	(23)	(19)	(19)	(14)
	Capex	0	0	0	0	0	0	0	0	0	0
	Free cash flow	(18)	(17)	(7)	(21)	(16)	(17)	(23)	(19)	(19)	(14)
Balance, $m
Balance, $m	Working capital	(4)	18	22	8	12	45	27	11	3	6
	Total debt	3	—	9	8	4	6	5	—	—	—
	Net debt	(4)	(24)	(18)	(7)	(13)	(44)	(30)	(16)	(6)	(9)
	Shareholders’ equity	7	27	21	15	19	56	29	13	4	7
Returns, %
Returns, %	ROA	(55.22)	(52.95)	(25.18)	(39.59)	(56.68)	(37.23)	(60.83)	(59.23)	(117.72)	(131.74)
	ROIC	(532.96)	(455.08)	(493.72)	(167.77)	(214.70)	(107.08)	0.00	0.00	0.00	0.00
	ROE	(162.69)	(124.13)	(49.97)	(95.15)	(129.54)	(55.83)	(84.34)	(91.37)	(211.21)	(256.41)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Dec 2022

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EVGN Evogene Ltd.	$6.3M	— (loss-making)	— (loss-making)	−35.02% (below 0%: shrinking)	n/m	+17.72% (above 0%: growing)	40.63%	(738.62%)	Compare
LEXX Lexaria Bioscience Corp.	$6.3M	— (loss-making)	— (loss-making)	−89.12% (below 0%: shrinking)	n/m	+53.90% (above 0%: growing)	100.00%	0.00%	Compare
ENVB Enveric Biosciences, Inc.	$6.2M	— (loss-making)	— (loss-making)	−7.28% (below 0%: shrinking)	n/m	−29.34% (below 0%: shrinking)	0.00%	0.00%	Compare
TRAW Traws Pharma, Inc.	$6.2M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−25.51% (below 0%: shrinking)	0.00%	0.00%	Compare
ALZN Alzamend Neuro, Inc.	$6.2M	— (loss-making)	—	—	n/m	+51.82% (above 0%: growing)	0.00%	0.00%	Compare
NRSN NeuroSense Therapeutics Ltd.	$6.0M	— (loss-making)	—	—	n/m	−23,458.82% (below 0%: shrinking)	—	0.00%	Compare
IMNN Imunon, Inc.	$6.0M	— (loss-making)	— (loss-making)	0.00%	n/m	−4.24% (below 0%: shrinking)	0.00%	0.00%
ORGS Orgenesis Inc.	$5.7M	— (loss-making)	1.0×	+82.42% (above 0%: growing)	n/m	−317.93% (below 0%: shrinking)	2,780.73%	(6,044.52%)	Compare
CANF Can-Fite Biopharma Ltd	$5.6M	— (loss-making)	— (loss-making)	−1.18% (below 0%: shrinking)	n/m	+12.63% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$6.2M	—	—	−21.15%	—	−6.44%	0.00%	0.00%

All 614 Biotechnology stocks →

Imunon, Inc. (IMNN) key facts

Imunon, Inc. (IMNN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
Imunon, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $500,000.00.
As of October 16, 2026, IMNN traded at $1.02, a market capitalization of $6.0 million.
Return on equity was −256.4% and debt-to-equity 1.32.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −12.47 (distress zone) for fiscal 2022.

Source: company filings (standardised) and stockrow calculations.